Synergy of the Bacteriocin AS-48 and Antibiotics Against Uropathogenic Enterococci

Overview

Journal Antibiotics (Basel)

Specialty Pharmacology

Date 2020 Sep 5

PMID 32887311

Citations 14

Authors

Manuel Montalban-Lopez

Ruben Cebrian

Rosa Galera

Lidia Mingorance

Antonio M Martin-Platero

Eva Valdivia

Manuel Martinez-Bueno

Mercedes Maqueda

Affiliations

Soon will be listed here.

Abstract

The genus comprises a ubiquitous group of Gram-positive bacteria that can cause diverse health care-associated infections. Their genome plasticity enables easy acquisition of virulence factors as well as antibiotic resistances. Urinary tract infections (UTIs) and catheter-associated UTIs are common diseases caused by enterococci. In this study, strains isolated from UTIs were characterized, showing that the majority were and contained several virulence factors associated to a better colonization of the urinary tract. Their susceptibility against the bacteriocin AS-48 and several antibiotics was tested. AS-48 is a potent circular bacteriocin that causes bacterial death by pore formation in the cell membrane. The interest of this bacteriocin is based on the potent inhibitory activity, the high stability against environmental conditions, and the low toxicity. AS-48 was active at concentrations below 10 mg/L even against antibiotic-resistant strains, whereas these strains showed resistance to, at least, seven of the 20 antibiotics tested. Moreover, the effect of AS-48 combined with antibiotics commonly used to treat UTIs was largely synergistic (with up to 100-fold MIC reduction) and only occasionally additive. These data suggest AS-48 as a potential novel drug to deal with or prevent enterococcal infections.

Citing Articles

The clinical praxis of bacteriocins as natural anti-microbial therapeutics.

Nisar S, Shah A, Nazir R Arch Microbiol. 2024; 206(11):451.

PMID: 39476181 DOI: 10.1007/s00203-024-04152-8.

Classification and Multi-Functional Use of Bacteriocins in Health, Biotechnology, and Food Industry.

Solis-Balandra M, Sanchez-Salas J Antibiotics (Basel). 2024; 13(7).

PMID: 39061348 PMC: 11273373. DOI: 10.3390/antibiotics13070666.

Synergistic Activity of Ingulados Bacteria with Antibiotics against Multidrug-Resistant Pathogens.

Blanco-Blanco J, Bravo M, Simon I, Fernandez-Llario P, Fajardo-Olivares M, Fernandez-Calderon M Antibiotics (Basel). 2024; 13(3).

PMID: 38534635 PMC: 10967309. DOI: 10.3390/antibiotics13030200.

Development of a Magnetic Bead-Based Method for Specific Detection of Using C-Terminal Domain of ECP3 Phage Endolysin.

Choi Y, Kim S, Kim J J Microbiol Biotechnol. 2023; 33(7):964-972.

PMID: 37164751 PMC: 10394340. DOI: 10.4014/jmb.2302.02033.

Advances in the preclinical characterization of the antimicrobial peptide AS-48.

Cebrian R, Martinez-Garcia M, Fernandez M, Garcia F, Martinez-Bueno M, Valdivia E Front Microbiol. 2023; 14:1110360.

PMID: 36819031 PMC: 9936517. DOI: 10.3389/fmicb.2023.1110360.

References

Wiegand I, Hilpert K, Hancock R . Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc. 2008; 3(2):163-75. DOI: 10.1038/nprot.2007.521. View

Heidari H, Hasanpour S, Ebrahim-Saraie H, Motamedifar M . High Incidence of Virulence Factors Among Clinical Enterococcus faecalis Isolates in Southwestern Iran. Infect Chemother. 2017; 49(1):51-56. PMC: 5382050. DOI: 10.3947/ic.2017.49.1.51. View

Maqueda M, Galvez A, Bueno M, Sanchez-Barrena M, Gonzalez C, Albert A . Peptide AS-48: prototype of a new class of cyclic bacteriocins. Curr Protein Pept Sci. 2004; 5(5):399-416. DOI: 10.2174/1389203043379567. View

Mathur H, Field D, Rea M, Cotter P, Hill C, Ross R . Bacteriocin-Antimicrobial Synergy: A Medical and Food Perspective. Front Microbiol. 2017; 8:1205. PMC: 5489601. DOI: 10.3389/fmicb.2017.01205. View

Garcia-Solache M, Rice L . The Enterococcus: a Model of Adaptability to Its Environment. Clin Microbiol Rev. 2019; 32(2). PMC: 6431128. DOI: 10.1128/CMR.00058-18. View

Ishikawa K, Hamasuna R, Uehara S, Yasuda M, Yamamoto S, Hayami H . Japanese nationwide surveillance in 2011 of antibacterial susceptibility patterns of clinical isolates from complicated urinary tract infection cases. J Infect Chemother. 2015; 21(9):623-33. DOI: 10.1016/j.jiac.2015.05.014. View

Zalipour M, Esfahani B, Halaji M, Azimian A, Havaei S . Molecular Characterization Of Vancomycin-Resistant Among Inpatients At Iranian University Hospitals: Clonal Dissemination Of ST6 And ST422. Infect Drug Resist. 2019; 12:3039-3047. PMC: 6768148. DOI: 10.2147/IDR.S217718. View

Abengozar M, Cebrian R, Saugar J, Garate T, Valdivia E, Martinez-Bueno M . Enterocin AS-48 as Evidence for the Use of Bacteriocins as New Leishmanicidal Agents. Antimicrob Agents Chemother. 2017; 61(4). PMC: 5365675. DOI: 10.1128/AAC.02288-16. View

Rostkowska O, Kuthan R, Burban A, Salinska J, Ciebiera M, Mlynarczyk G . Analysis of Susceptibility to Selected Antibiotics in and Causing Urinary Tract Infections in Kidney Transplant Recipients over 8 Years: Single-Center Study. Antibiotics (Basel). 2020; 9(6). PMC: 7344424. DOI: 10.3390/antibiotics9060284. View

10.

Fernandez-Cuenca F, Martinez-Martinez L, Pascual A, de Cueto M, Gutierrez O, Nieto J . Evaluation of the WIDER I system for antimicrobial susceptibility testing of clinical isolates of Haemophilus influenzae and Streptococcus pneumoniae. Clin Microbiol Infect. 2003; 9(5):449-52. DOI: 10.1046/j.1469-0691.2003.00580.x. View

11.

Maqueda M, Sanchez-Hidalgo M, Fernandez M, Montalban-Lopez M, Valdivia E, Martinez-Bueno M . Genetic features of circular bacteriocins produced by Gram-positive bacteria. FEMS Microbiol Rev. 2007; 32(1):2-22. DOI: 10.1111/j.1574-6976.2007.00087.x. View

12.

Aguilar-Perez C, Gracia B, Rodrigues L, Vitoria A, Cebrian R, Deboosere N . Synergy between Circular Bacteriocin AS-48 and Ethambutol against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2018; 62(9). PMC: 6125546. DOI: 10.1128/AAC.00359-18. View

13.

Ben Omar N, Castro A, Lucas R, Abriouel H, M K Yousif N, Franz C . Functional and safety aspects of Enterococci isolated from different Spanish foods. Syst Appl Microbiol. 2004; 27(1):118-30. DOI: 10.1078/0723-2020-00248. View

14.

Portillo A, Ruiz-Larrea F, Zarazaga M, Alonso A, Martinez J, Torres C . Macrolide resistance genes in Enterococcus spp. Antimicrob Agents Chemother. 2000; 44(4):967-71. PMC: 89799. DOI: 10.1128/AAC.44.4.967-971.2000. View

15.

OBrien V, Hannan T, Nielsen H, Hultgren S . Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections. Microbiol Spectr. 2016; 4(1). PMC: 4887100. DOI: 10.1128/microbiolspec.UTI-0013-2012. View

16.

Flores-Mireles A, Walker J, Caparon M, Hultgren S . Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015; 13(5):269-84. PMC: 4457377. DOI: 10.1038/nrmicro3432. View

17.

Martin-Escolano R, Cebrian R, Martin-Escolano J, Rosales M, Maqueda M, Sanchez-Moreno M . Insights into Chagas treatment based on the potential of bacteriocin AS-48. Int J Parasitol Drugs Drug Resist. 2019; 10:1-8. PMC: 6447751. DOI: 10.1016/j.ijpddr.2019.03.003. View

18.

Abat C, Huart M, Garcia V, Dubourg G, Raoult D . Enterococcus faecalis urinary-tract infections: Do they have a zoonotic origin?. J Infect. 2016; 73(4):305-13. DOI: 10.1016/j.jinf.2016.07.012. View

19.

Sanchez-Barrena M, Martinez-Ripoll M, Galvez A, Valdivia E, Maqueda M, Cruz V . Structure of bacteriocin AS-48: from soluble state to membrane bound state. J Mol Biol. 2003; 334(3):541-9. DOI: 10.1016/j.jmb.2003.09.060. View

20.

Eckert R . Road to clinical efficacy: challenges and novel strategies for antimicrobial peptide development. Future Microbiol. 2011; 6(6):635-51. DOI: 10.2217/fmb.11.27. View